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ABSTRACT: Optogenetic control of endogenous signaling can be an
important tool for probing cell behavior. Using the photoresponse of
the LOV2 domain of Avena sativa phototropin 1, we developed
analogues of kinase inhibitors whose activity is light dependent.
Inhibitory peptides were appended to the Jα helix, where they potently
inhibited kinases in the light but were sterically blocked from kinase
interaction in the dark. Photoactivatable inhibitors for cyclic-AMP
dependent kinase (PKA) and myosin light chain kinase (MLCK) are
described, together with studies that shed light on proper positioning of the peptides in the LOV domain. These inhibitors
altered endogenous signaling in living cells and produced light-dependent changes in cell morphodynamics.
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Protein phosphorylation is a ubiquitous and essentialmechanism of cell regulation and plays important roles
in pathology.1 This reaction is catalyzed by a large superfamily
of kinases, which accounts for nearly 2% of the genes in the
human genome.2,3 Studying kinase function using genetic
manipulation or small-molecule pharmacological agents
provides poor spatial and/or temporal resolution, limiting our
ability to examine how subcellular localization and the kinetics
of protein phosphorylation contribute to regulation. New
molecular tools are needed to probe the role of kinases in
native cellular environments.
There has been considerable progress in developing
genetically encoded, light-controlled molecules that can
manipulate biological processes in living cells and animals.
Many of these applications utilize analogues of proteins, where
the protein of interest has been fused to light-responsive
protein domains, or to proteins that interact with such domains
(reviewed in the literature4). This can affect the normal
biological activity of the target protein and is typically
implemented through overexpression of ectopic proteins.
Recently, the light-sensitive LOV2 domain from Avena sativa
phototropin 1 (here referred to as LOV2) was adapted to
control the activity of peptides.5,6 We extend this work to
control peptides that inhibit kinases and demonstrate that the
approach can control endogenous kinases in living cells.
LOV2 is a member of the PAS superfamily.7 It contains a
flavin mononucleotide (FMN) cofactor located in the center of
the PAS fold and a large α-helical region at the C-terminus of
the fold termed the Jα helix.8,9 Upon exposure to blue light, a
covalent adduct is formed between the FMN and a cysteine
side chain in the PAS fold, leading to a large conformational
change that ultimately causes the unfolding of the Jα helix
(Figure 1A).7,10−12 When irradiation ceases, reversion of the
thiol bond and a conformational change back to the dark state
occurs.13 We hypothesized that these conformational changes
could be used to control inhibitory peptides with light,
providing a selective and minimally invasive way to manipulate
endogenous signaling pathways in vivo.
We began our study by choosing regions within the LOV2
sequence that could serve as sites for peptide incorporation,
where light-induced conformational changes might affect
exposure of the peptide. We first selected the flexible loop
between the PAS fold of LOV2 and the Jα helix (Figure 1B).
For our initial studies, we selected the widely used naturally
occurring PKA inhibitory peptide PKI. The PKI gene encodes a
heat-stable, 76-amino acid peptide that acts as a high-affinity,
highly selective competitive inhibitor of the catalytic subunit of
PKA (Ki 2.5−36 nM).
14 The pseudosubstrate region of PKI is
between amino acids 18−22, and PKI is commonly used as a
17-amino acid fragment encompassing amino acids 6−22 (PKI
6−22), or as a shorter 9-amino acid fragment encompassing
amino acids 14−22 (PKI 14−22). Moreover, the expression of
PKI fusion proteins has been shown to effectively dampen PKA
signaling in living cells.15,16 We incorporated the shorter PKI
14−22 between the Thr517 and Glu518 residues of the LOV2
sequence along with flanking Gly-Ser linkers to retain peptide
flexibility (PKI 14−22 Int; Figure 1B). We expressed a “dark
state” mutant (C450A) of LOV2 that abolishes FMN-thiol
bond formation,17 or a “lit state” mutant (I539E) that
Special Issue: Synthetic Photobiology
Received: March 7, 2014
Published: June 6, 2014
Letter
pubs.acs.org/synthbio
© 2014 American Chemical Society 788 dx.doi.org/10.1021/sb5001356 | ACS Synth. Biol. 2014, 3, 788−795
This is an open access article published under an ACS AuthorChoice License, which permits
copying and redistribution of the article or any adaptations for non-commercial purposes.
destabilizes the Jα helix10 in HEK293 cells. PKA activity was
stimulated using the adenylyl cyclase agonist forskolin (10 μM,
1.5 h), and PKA activity monitored by Western blot using an
antibody that specifically recognizes phosphorylated PKA
motifs.18 We found that both C450A and I539E mutants
were able to inhibit PKA activity (Figure 1C,D; C450A, 29.6 ±
5.9%; I539E, 41.2 ± 4.5% compared to LOV2 alone). As it was
unlikely that the peptide could adopt a PKA-interacting
conformation in both the lit and dark state structures, this
data suggested that peptide incorporation at this site altered the
folding of LOV2. In a previous study, our laboratory created a
photoswitchable version of the Rac GTPase using LOV2 (PA-
Rac).19 By incorporating the PKI sequence into this construct
at the loop position described above (between Thr517 and
Glu518), we could test whether peptide incorporation affected
light-induced conformational changes. Light-dependence of Rac
activity was examined using a previously established bio-
chemical method for assessing Rac activation, in which Rac was
pulled down with the CRIB domain of the Rac effector p-21
activated kinase (Figure S1B, Supporting Information).20
Indeed, pulldown of wild-type PA-Rac increased with light,
but the light response was lost with loop incorporation of PKI
(Figure S1, Supporting Information).
On the basis of our previous studies of peptide interactions
with the Jα helix,5,6 we next examined whether we could cage
PKI by embedding it in the C-terminus of this helix. The three-
dimensional structure of LOV2-PKI C-terminal fusions were
modeled using the I-TASSER algorithm.21,22 Intriguingly,
whereas PKI 6−22 became unstructured at its C-terminal
end, PKI 14−22 remained helical within the Jα helix, suggesting
that the length of the peptide sequence may predominantly
determine the success of C-terminal peptide incorporation
(Figure 2A−C). Experiments were consistent with this
Figure 1. Perturbation of dark-state LOV2 due to peptide
incorporation in the Jα loop. (A) Schematic showing the light
response of LOV2. Blue represents the LOV2 globular domain, yellow
represents the Jα helix. Upon irradiation with blue light, a
conformational change in LOV2 causes the unwinding of Jα. (B)
Crystal structure of LOV2 showing the PAS fold of LOV2 (blue), the
Jα helix (yellow), and the loop region connecting the two domains
(arrowhead). The sequence of PKI and its incorporation between
Thr517 and Glu518 are shown in the box. (C) Western blot showing
total phosphorylated PKA substrates in HEK293 cells and actin
loading control. Note the loss of PKA phosphorylation in both dark-
state mutant (C450A) and light-state mutants (I539E). (D)
Quantification of (C), n = 4, *p < 0.01, Student’s t test.
Figure 2. Photoswitchable response of LOV2-PKI 14−22. (A) I-
TASSER prediction of the structure of LOV2-PKI 6−22 and LOV2-
PKI 14−22 (B). The Jα helix (yellow), the PKI 14−22 sequence (red),
and the variable linker region of PKI 6−22 (green) are indicated. (C)
Sequence showing the C-terminal fusion of PKI to LOV2. Amino acids
537−541 are shown for LOV2 in yellow. Green represents the variable
PKI sequence and red the core PKI inhibitory region. (D) Western
blot showing the dark and light response of LOV2-PKI 6−22 and
LOV2-PKI 14−22, LOV2-PKI 6−22Phe, and actin loading control.
Note the inhibition of phosphorylation in LOV2-PKI 14−22 only
upon irradiation. LOV2-PKI 6−22Phe is shown in the dark. (E)
Quantification of (D), n = 4, *p < 0.01, Student’s t test. (F) Western
blot showing the recovery of PKA signaling upon cessation of light
stimulation. (G) Quantification of (F), n = 4, *p < 0.01, Student’s t
test.
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prediction: LOV2-PKI 6−22 inhibited induction of PKA
signaling in both the light and the dark (Figure 2D,E; Dark,
33.3 ± 14.2% of control; Light, 24.1 ± 12.0% of control), but
for cells expressing LOV2-PKI 14−22, PKA induction was
substantially reduced in the light but not in the dark (Figure
2D,E; Dark, 98.4 ± 5.1% of control; Light, 52.5 ± 14.6%). In
previous work we described an interaction between a C-
terminal phenylalanine and a hydrophobic patch within LOV2
that could enhance light dependent caging of C terminal
peptides on LOV.5 However, this failed to have an effect here
(LOV2-PKI 6−22Phe, Figure 2D,E; 24.0 ± 19.8% of control).
We found that the C-terminal fusion of PKI inhibited PKA
signaling to a similar degree as cell-permeable PKI peptide
(Figure S2, Supporting Information). Moreover, in reversibility
assays, we found that PKA activity returned to basal states
between 15−40 min after the cessation of blue light (Figure
2F,G; 0 min, 39.8 ± 7.8%; 2 min, 36.1 ± 9.9%; 8 min, 40.4 ±
6.1%; 15 min, 78.6 ± 15.0%; 40 min, 126.1 ± 27.4%). These
results demonstrate that the C-terminal fusion of PKI could
effectively inhibit PKA signaling in the presence of blue light in
a reversible manner.
We renamed the LOV2-PKI 14−22 construct photo-
activatable PKI (PA−PKI) and performed a set of experiments
to determine its utility in living cells. In order to test the
response of PA−PKI to light, we followed PKA-dependent
phosphorylation of a single PKA substrate. We irradiated cells
with blue light using a 460 nm LED array and monitored
forskolin-dependent phosphorylation of cAMP response
element-binding protein (CREB). CREB is a transcription
factor that is activated through phosphorylation at Ser133 by an
ensemble of kinases including PKA, protein kinase C (PKC),
Ca2+/calmodulin-dependent kinase (CaMK), p90Rsk, and
MAPKAPK-223−28 (Figure 3A). We saw no effect on CREB
induction using PA−PKI C450A in the light or PA−PKI WT in
the dark (Figure 3B,C; C450A Light, 101.6 ± 1.7%; WT Dark,
98.7 ± 7.8% of control). In contrast, PA−PKI in the light
produced a substantial reduction in forskolin-induced PKA
phosphorylation that was comparable to that produced by
existing reagents in previously published reports29−32 (46.8 ±
10.4% of control; see Figure S2, Supporting Information, for
comparison).
An important advantage of PA−PKI is its ability to affect
PKA signaling in a subset of cells within a population. Primary
cultured mouse cortical neurons aged 6 days in vitro (DIV 6)
were sparsely transfected with PA−PKI or PA−PKI C450A for
48 h and stimulated with forskolin in the presence of blue light.
Whereas a robust signal for phosphorylated PKA substrates was
seen in the majority of cells, neurons expressing PA−PKI, but
not PA−PKI C450A, showed a substantial decrease in PKA
activity (Figure 4). When quantified, irradiation of cells
expressing PA−PKI diminished PKA phosphorylation by
∼47% (Figure 4B; fluorescence intensity, C450A, 725.8 ±
48.07; WT, 390.9 ± 24.63). Together, these results
demonstrate the ability of PA−PKI to target endogenous
signaling events in living cells in a light-dependent manner.
We next asked if we could apply our methods to create
additional photoswitchable inhibitory peptides. To this end, we
selected myosin light chain kinase inhibitor peptide 18
(MKI).33 Like CREB, myosin light chain 2, also known as
myosin regulatory light chain, is targeted for phosphorylation
by multiple kinases. These include myosin light chain kinase,34
Rho kinase,35 and the cell cycle regulator Cdc236 (Figure 5A).
We employed a design similar to that used for PA−PKI, fusing
MKI to the C-terminus of Jα with a single glycine linker. I-
TASSER modeling of this sequence showed that MKI adopted
a helical conformation similar to PA−PKI (Figure 5B). When
tested in HEK293 cells, we saw a dramatic light-dependent
decrease in cellular levels of phosphorylated myosin light chain
(Figure 5C,D). Phosphorylated myosin light chain levels were
unaffected in irradiated cells expressing PA-MKI C450A and in
nonirradiated cells expressing PA-MKI WT (Figure 5D;
C450A, 92.4 ± 7.8%; WT, 93.8 ± 4.6% of control), while
irradiated cells expressing PA-MKI exhibited a ∼70% decrease
in phosphorylation (Figure 5D; 30.4 ± 8.1% of control).
Given the role of myosin light chain kinase on peripheral
membrane movements,34 we expressed PA-MKI in COS-7 cells
and examined its effects on the protrusive activity of living cells
(Figure 6). These cells exhibit a wide variation of protrusion
and retraction behaviors, both within a cell and between cells.
Not only is MLC phosphorylation modulated in parallel by
multiple kinases, these cell morphodynamic behaviors are
controlled by a wide-range of other cytoskeleton processes that
are independent of myosin activity. Therefore, we expected that
acute inhibition of MLCK by PA-MKI might generate subtle
effects. Indeed, histograms of local edge velocities (see
Methods) in the absence (dark) and presence (light) of
activated PA-MKI showed no obvious trends compared to the
large spread of the distributions (Figure 6A).
To analyze the morphodynamic behaviors more systemati-
cally, we separated protrusion and retraction events and
quantified the persistence (duration) and maximal velocity
per event. To integrate data from multiple cells we normalized
the distributions relative to the median duration and maximal
velocities, respectively, during the first dark phase of the
Figure 3. Light-dependent inhibition of CREB phosphorylation by
PA−PKI. (A) Schematic showing pathway-dependent specificity of
PA−PKI in CREB phosphorylation. (B) Loss of phosphorylated
CREB (pCREB) but not total CREB upon irradiation in HEK293
cells. (C) Quantification of (B), n = 3, *p < 0.01, Student’s t test.
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experiment. Neither median values for the normalized
distributions from cells expressing LOV2 alone, nor those
expressing PA-MKI showed a statistically significant difference
between the dark and light phases (Figure 6D,G). However, the
variation between the whisker lengths of the distribution box
plots for cells expressing PA-MKI indicated that optical
activation of the inhibitor affected the extreme ranges of
protrusion velocities. We therefore generated separate dis-
tributions of the top (>75%) and bottom (<25%) quartiles
(Figure 6B,C,E,F). These analyses revealed that light had no
effect on control cells expressing LOV2 alone, but membrane
protrusions, and not retractions, were dampened by PA-MKI
activation (Figure 6 and Figure S3, Supporting Information).
Simply using the membrane permeable MLCK inhibitory
peptide 18 produced a dampening of protrusion velocities
similar to that of PA-MKI (Figure S4, Supporting Information).
These observations are consistent with previous studies
showing that myosin light chain kinase plays a role in
phosphorylating peripheral myosin light chain to control the
structure of actin networks.34 Moreover, these results
demonstrate the utility of photoactivatable peptides in isolating
distinct signaling pathways within living cells.
In summary, we report the development of photoswitchable
inhibitory peptides that target endogenous kinase signaling. We
leveraged the large structural changes that occur during LOV2
irradiation to produce light-responsive kinase inhibitors. Within
the field of cell signaling, a great challenge has been to
distinguish between competing signaling pathways within a cell.
Phosphorylation sites within substrate proteins are often
targeted by multiple kinases, and there are currently limited
approaches to dissect the biological roles of distinct pathways in
cells. Our method provides a minimally invasive approach to
address these challenges with high spatiotemporal precision.
Peptides are competitive inhibitors of many classes of enzymes
and serve a broad range of biological roles, including allosteric
modulation37 and directing the subcellular localization of
proteins.38 Novel classes of peptide therapeutics have been
proposed ranging from noncompetitive kinase inhibitors39 to
peptides that regulate angiogenesis,40 the Rho GTPases,41 and
viral infection.42,43 The methods described here should be
applicable to many other peptides, for investigation and
manipulation of processes beyond kinase function.
■ METHODS
1.1. Antibodies and Reagents. Antiphospho-PKA sub-
strate (RRXS*/T*), antiphospho-CREB (Ser133), anti-CREB,
antiphospho-myosin regulatory light chain (Ser19), and
antimyosin regulatory light chain were purchased from Cell
Signaling Technology. Anti-GFP (JL-8) was purchased from
Clontech, anti-β-Actin was purchased from Millipore. Forskolin
was purchased from Tocris bioscience. All restriction enzymes
were purchased from New England Biolabs. HEK293 cells
(ATCC) were cultured in a 5% CO2 humidified incubator in
DMEM, 10% (v/v) fetal bovine serum (Hyclone) and 2 mM
Glutamax (Invitrogen). Transfections were performed in 6-well
Figure 4. Inhibition of forskolin-induced PKA phosphorylation in primary cultured cortical neurons by PA−PKI. (A) Immunofluorescence of total
phosphorylated PKA substrates (pPKA substrate) in cells expressing mVenus−PA-PKI or the dark-state mutant (C450A) of mVenus−PA-PKI.
Arrows indicate transfected neurons. Arrowheads indicate untransfected nearby neurons. (B) Fluorescence intensity quantification of (A), n = 20
cells per group, *p < 0.01, Student’s t test.
Figure 5. Construction of a photoactivatable myosin light chain kinase
inhibitor (PA-MKI). (A) Schematic showing kinases that phosphor-
ylate regulatory myosin light chain. (B) I-TASSER prediction of the
conformation for PA-MKI. (C) Western blot showing a reduction of
phosphorylated myosin light chain (pMLC) but not total (MLC) in
response to blue light irradiation. (D) Quantification of (C), n = 3, *p
< 0.01, Student’s t test.
ACS Synthetic Biology Letter
dx.doi.org/10.1021/sb5001356 | ACS Synth. Biol. 2014, 3, 788−795791
Figure 6. Changes in the protrusion dynamics of COS-7 cells in response to PA-MKI activation. (A) Snapshot of raw image data before (left),
during (center), and after (right) light stimulation of a cell expressing PA-MKI. Colors represent the cell edge over the entire imaging interval (blue,
early time points; red, late time points). Histograms of instantaneous edge velocity for the three imaging intervals are shown below. (B−D) Box plots
showing normalized distributions of protrusion persistence (duration of protrusion phase; red boxes) and maximum velocity per protrusion event
(green boxes) for cells expressing LOV2. The three plots represent normalized distributions of the >75th (left), <25th (center), and total (right).
Boxes within each plot represent the distributions before (left; gray fill), during (center; white fill), and after (right; gray fill) light stimulation. Data
was derived from n = 6 cells expressing LOV2 domain only (control). (E−G) Box plots showing normalized distributions of protrusion persistence
(duration of protrusion phase; red boxes) and maximum velocity per protrusion event (green boxes) for cells expressing PA-MKI. The three plots
represent normalized distributions of the >75th (left), <25th (center), and total (right). Boxes within each plot represent the distributions before
(left; gray fill), during (center; white fill), and after (right; gray fill) light stimulation. Data was derived from n = 6 cells expressing PA−PKI. Note the
decrease in maximum velocity in the <25th percentile of control cells, presumably due to irradiation toxicity. However, in contrast to the decrease in
cells expressing PA-MKI, this shift is statistically nonsignificant. *p < 0.01, Anderson−Darling test. A detailed description of the analyses can be
found in the Methods.
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dishes using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions.
1.2. Molecular Biology. Inhibitory peptides were fused to
the C-terminus of the Jα helix of the LOV domain of Avena
sativa phototropin 1 (404−541) by polymerase chain reaction
and cloned into pmVenus-C1 using XhoI and EcoRI sites.
Primer sequences used are as follows: LOV2 sense (5′-
CTCGAGAAATGGGATCCTTGGCTACTACACTTG-3′),









1.3. Light Irradiation Assay. Cells (HEK293 or neurons)
expressing the appropriate constructs were irradiated in an
incubator with blue light generated from a 30 W, 30.5 cm × 17
cm panel containing an array of 711 light-emitting diodes
(LEDs) radiating 460 nm light (LEDs Super Bright). Cells
were irradiated at a distance of 9 cm, which produced a light
intensity of 5.6 mW/cm2. For PKA assays, plates containing
transfected cells were placed under the LED array for 15 min
prior to the addition of forskolin. Plates were placed back into
the incubator and irradiated for an additional 1.5 h. For MLCK
assays, cells were irradiated in the incubator for 1−1.5 h. Cells
were lysed in NuPage LDS sample buffer (Life Technologies)
supplemented with 1% β-mercaptoethanol, 1× Complete Mini
protease inhibitor cocktail (Roche), and 1× Halt Phosphatase
Inhibitor Cocktail (Thermo Scientific).
1.4. Dissociated Neuron Cultures. Mouse cortices were
dissected from embryonic day (E) 13.5 to E 16.5 animals,
trypsinized with TrypLE express at 37°C for 10 min, and
dissociated with a fire-polished Pasteur pipet in plating medium
(Neurobasal medium with 5% fetal bovine serum, Glutamax,
B27 (Invitrogen), and Antibiotic-Antimycotic (Invitrogen)).
Dissociated neurons were seeded onto 24-well plates
containing coverslips coated with poly-D-lysine (0.1 mg/mL)
at a density of 1 × 105 cells/well. Neurons were incubated at 37
°C with 5% CO2 and the plating medium changed into
Neurobasal medium supplemented with 4.84 mg/mL Uridine
5′-triphosphate (Sigma), 2.46 mg/mL 5-fluoro 2-deoxyuridine
(Sigma), Glutamax, B27, and Antibiotic-Antimycotic at days in
vitro (DIV) 3 and DIV 6. Neurons were transfected on DIV 6
with various DNA constructs using Lipofectamine 2000. After
48 h in culture, neurons were irradiated upon PKA induction
with forskolin and fixed with 4% paraformaldehyde (PFA)/4%
sucrose in phosphate buffered saline for 30 min.
1.5. Immunohistochemistry. Freshly fixed neurons were
washed with PBS and permeabilized and blocked with 8%
bovine serum albumin (BSA) in PBS containing 0.1% Triton X-
100. Neurons were then incubated with primary antibodies at 4
°C overnight. After washing with PBS, appropriate Alexa Fluor-
conjugated secondary antibodies (Life Technologies) were
used to detect the signal. The secondary antibody was
incubated at room temperature for 1 h. Coverslips were
mounted onto glass slides using Fluoro-Gel mounting medium
(Electron Microscopy Sciences). To quantify PKA activity in
neurons, Metamorph software (Molecular Devices) was used to
create a binary mask of the cells from the mVenus images. This
defined the area of the transfected cell of interest. The average
intensity of the immunofluorescence signal produced from
staining with the antiphospho-PKA substrate antibody was
measured within this defined region.
1.6. Live Cell Imaging. COS-7 cells were transiently
cotransfected with LifeAct-mCherry 20−28 h before imaging.
Cells used for live cell imaging were seeded on coverslips
coated with 10 mg/mL fibronectin in Ham’s F-12K medium
free of Phenol Red and containing 5% FBS. Coverslips were
mounted in an Attofluor live cell chamber (Invitrogen) placed
on a heated microscope stage (Warner). Images were acquired
using an Olympus IX81-ZDC microscope equipped with a
CoolSNAP HQ2 14-bit camera (Photometrics). Bandpass and
neutral density filters (Chroma) were switched using motorized
filter wheels (Ludl Electronic Products) controlled by
Metamorph Software version 7.6.4. YFP and mCherry images
were acquired using a 100 W Hg arc lamp with a 1% ND filter,
and 510−520 nm or 565−595 nm band-pass filters respectively,
for 500 ms. For peptide activation, a 5% ND filter and a 426−
446 nm band-pass filter were used. The activation period of
imaging consisted of a pulse protocol (alternating 5 s light 5 s
dark) that lasted a total of 15 min. Images were processed post
acquisition via shading correction, background subtraction, and
binary masking using Metamorph software (Molecular
Devices).
1.7. Image Analysis. The images acquired by live-cell
microscopy were analyzed using in-house software. For each
frame of the movie, the cell edge was first detected and then
divided into a series of 1 μm2 wide segments, as described in.44
Local cell edge velocities were calculated by tracking the
displacement of segments from one frame to the next. Per-
segment velocity time series were then divided into protrusion
and retraction events, and for each event the duration and
maximal velocity recorded. In order to quantify changes in
these parameters between the initial basal (dark), stimulated
(light), and recovery (dark) imaging intervals, the distributions
were normalized by the median value of the basal interval. This
normalization corrected for distribution bias associated with the
heterogeneity of morphodynamic behavior among cells. Both
persistence and max protrusion/retraction velocities approx-
imately followed a log-normal distribution. The Anderson−
Darling Test was used on the exponentiated values to
determine the significance of observed differences among the
distributions collected from the three imaging intervals.
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